-+ 0.00%
-+ 0.00%
-+ 0.00%

Cardiol Therapeutics Announces Publication Of Results From Phase II ARCHER Study In ESC Heart Failure, Journal Of European Society Of Cardiology

Benzinga·02/10/2026 12:30:12
Listen to the news

Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced the publication of results from its Phase II ARCHER study in ESC Heart Failure, a journal of the European Society of Cardiology.

The peer-reviewed article reports results from a randomized, double-blind, placebo-controlled trial evaluating CardiolRx™, Cardiol's lead oral drug candidate, in 109 patients with acute myocarditis using advanced cardiac magnetic resonance (CMR) imaging measures of myocardial inflammation and remodelling.